SCHEMBL17599470

SCHEMBL17599470

COC(=O)c1cc(-c2cc(NS(=O)(=O)c3c(C)c(C)cc(C)c3C)c3ccccc3c2)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ ACLY P53396 11/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ KEAP1 Q14145 3/20 0.37
▸ NFE2L2 Q16236 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599423 0.90 ALDH1A1 (0.56) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599324 0.84 MEN1 (0.47) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599435 0.81 ALDH1A1 (0.57) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599483 0.80 MEN1 (0.56) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599467 0.79 KMT2A (0.55) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599466 0.77 KMT2A (0.51) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599527 0.77 SLC6A3 (0.53) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599510 0.77 KMT2A (0.53) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599463 0.76 ALDH1A1 (0.57) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL17599429 0.75 KMT2A (0.51) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998295-A1 Aryl substituted naphthyl sulfonamide derivatives as keap-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
EP-2998295-A1 Aryl substituted naphthyl sulfonamide derivatives as keap-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback